Nifty
:
11274.20
Sensex
:
38014.62
569.40 (5.32%)
1921.15 (5.32%)
Nifty
Sensex
:
:
11274.20
38014.62
569.40 (5.32%)
1921.15 (5.32%)

Lupin Ltd.

Pharmaceuticals & Drugs

Rating :
64/99

BSE: 500257 | NSE: LUPIN

NSE BSE
756.30
20-Sep-2019
  • Open
  • High
  • Low
  • Previous Close
  •  747.70
  •  758.85
  •  734.15
  •  741.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2689710
  •  20174.74
  •  918.00
  •  697.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 34,224.68
  • 48.42
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 41,733.63
  • 0.66%
  • 2.48

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.96%
  • 1.11%
  • 11.21%
  • FII
  • DII
  • Others
  • 0.37%
  • 12.94%
  • 27.41%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.13
  • 5.54
  • -1.50

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.35
  • -4.45
  • -8.50

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.32
  • -24.16
  • -38.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.12
  • 28.29
  • 22.98

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.54
  • 5.21
  • 3.36

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.97
  • 16.41
  • 13.50

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
4,418.38
3,855.93
14.59%
4,406.32
4,033.83
9.23%
4,504.87
3,975.62
13.31%
3,951.06
3,951.96
-0.02%
Expenses
3,558.16
3,328.96
6.89%
3,534.03
3,325.08
6.28%
3,752.33
3,287.28
14.15%
3,401.42
3,098.91
9.76%
EBITDA
860.22
526.97
63.24%
872.29
708.75
23.07%
752.54
688.34
9.33%
549.64
853.05
-35.57%
EBIDTM
19.47%
13.67%
19.80%
17.57%
16.70%
17.31%
13.91%
21.59%
Other Income
72.21
184.20
-60.80%
86.50
144.92
-40.31%
43.42
28.42
52.78%
230.68
74.04
211.56%
Interest
85.62
68.72
24.59%
85.52
58.53
46.11%
79.77
54.00
47.72%
73.82
47.92
54.05%
Depreciation
317.09
258.98
22.44%
280.78
272.83
2.91%
279.76
280.35
-0.21%
265.49
272.18
-2.46%
PBT
529.72
383.47
38.14%
594.73
-942.04
-
94.21
382.41
-75.36%
441.01
606.99
-27.34%
Tax
227.98
181.14
25.86%
299.84
-163.18
-
247.80
160.77
54.13%
172.91
154.06
12.24%
PAT
301.74
202.33
49.13%
294.89
-778.86
-
-153.59
221.64
-
268.10
452.93
-40.81%
PATM
6.83%
5.25%
6.69%
-19.31%
-3.41%
5.58%
6.79%
11.46%
EPS
6.70
4.48
49.55%
6.40
-17.33
-
-3.35
4.91
-
5.88
10.07
-41.61%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
17,280.63
16,718.18
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
4,870.79
Net Sales Growth
9.25%
5.78%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
19.47%
 
Cost Of Goods Sold
5,951.65
5,234.59
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
1,821.29
Gross Profit
11,328.98
11,483.59
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
3,049.50
GP Margin
65.56%
68.69%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
62.61%
Total Expenditure
14,245.94
13,835.96
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
3,886.90
Power & Fuel Cost
-
475.51
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
154.66
% Of Sales
-
2.84%
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
3.18%
Employee Cost
-
3,151.29
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
549.96
% Of Sales
-
18.85%
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
11.29%
Manufacturing Exp.
-
2,030.42
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
500.14
% Of Sales
-
12.14%
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
10.27%
General & Admin Exp.
-
1,429.32
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
292.37
% Of Sales
-
8.55%
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
6.00%
Selling & Distn. Exp.
-
1,298.77
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
446.97
% Of Sales
-
7.77%
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
9.18%
Miscellaneous Exp.
-
216.06
166.20
283.61
204.82
271.21
283.96
184.88
162.80
130.76
446.97
% Of Sales
-
1.29%
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
2.49%
EBITDA
3,034.69
2,882.22
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
983.89
EBITDA Margin
17.56%
17.24%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
20.20%
Other Income
432.81
364.02
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
14.20
Interest
324.73
307.83
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
38.49
Depreciation
1,143.12
1,085.01
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
123.91
PBT
1,659.67
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Tax
948.53
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
136.02
Tax Rate
57.15%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
16.28%
PAT
711.14
602.80
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
688.51
PAT before Minority Interest
702.79
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
699.67
Minority Interest
-8.35
-8.93
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
-11.16
PAT Margin
4.12%
3.61%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
14.14%
PAT Growth
625.36%
143.32%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
25.57%
 
Unadjusted EPS
15.63
13.41
5.56
56.69
50.25
53.54
40.99
29.39
19.43
19.36
15.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
2,567.83
Share Capital
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
88.94
Total Reserves
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
2,478.35
Non-Current Liabilities
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
1,283.35
Secured Loans
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
872.24
Unsecured Loans
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
267.61
Long Term Provisions
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
0.00
Current Liabilities
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
1,189.25
Trade Payables
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
883.52
Other Current Liabilities
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
82.82
Short Term Borrowings
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
0.00
Short Term Provisions
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
222.91
Total Liabilities
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92
Net Block
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
1,906.17
Gross Block
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
2,613.39
Accumulated Depreciation
4,645.17
2,459.58
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
707.22
Non Current Assets
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
2,290.47
Capital Work in Progress
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
348.80
Non Current Investment
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
26.43
Long Term Loans & Adv.
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
0.00
Other Non Current Assets
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
0.00
Current Assets
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
2,775.45
Current Investments
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
0.00
Inventories
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
971.49
Sundry Debtors
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
1,126.57
Cash & Bank
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
201.53
Other Current Assets
1,769.95
621.30
533.43
479.44
534.98
532.99
572.33
427.17
628.48
475.86
Short Term Loans & Adv.
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
475.86
Net Current Assets
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
1,586.20
Total Assets
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
5,065.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
676.41
PBT
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
835.69
Adjustment
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
144.33
Changes in Working Capital
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
-136.62
Cash after chg. in Working capital
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
843.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
-166.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,282.47
-1,407.27
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
-680.17
Net Fixed Assets
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
-309.75
Net Investments
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
-250.20
Others
-794.29
-1,564.03
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
-120.22
Cash from Financing Activity
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
136.13
Net Cash Inflow / Outflow
-872.37
-1,148.18
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
132.37
Opening Cash & Equivalents
1,416.43
2,799.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
68.08
Closing Cash & Equivalent
544.06
1,651.29
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88
197.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
57.73
ROA
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
15.44%
ROE
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
35.05%
ROCE
8.48%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
27.51%
Fixed Asset Turnover
1.95
1.20
1.62
1.80
2.15
2.28
2.19
1.99
2.10
2.06
Receivable days
65.46
109.70
92.39
92.24
72.65
74.67
74.61
77.76
74.26
76.18
Inventory Days
47.47
84.35
72.15
73.96
65.73
65.48
69.24
75.12
67.69
71.86
Payable days
59.26
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
64.47
Cash Conversion Cycle
53.67
125.48
104.91
103.00
73.94
76.37
80.10
88.76
80.49
83.57
Total Debt/Equity
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
0.44
Interest Cover
5.92
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84
22.71

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Lupin receives sANDA approval from USFDA for Levothyroxine Sodium Tablets
    20th Sep 2019, 15:55 PM

    The company’s Levothyroxine Sodium Tablets are indicated for Hypothyroidism and Pituitary Thyrotropin Suppression

    Read More
  • Lupin gets warning letter from USFDA for Mandideep (Unit-1) facility
    19th Sep 2019, 10:25 AM

    The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility

    Read More
  • Lupin receives USFDA's approval for Ethacrynic Acid Tablets
    9th Sep 2019, 15:07 PM

    The company’s Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc

    Read More
  • Lupin partners with Boehringer lngelheim
    4th Sep 2019, 12:41 PM

    The partnership aims to develop Lupin's lead MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers

    Read More
  • Lupin’s arm inks commercial agreement with Creso for hemp oil based cannaQIX
    26th Aug 2019, 15:18 PM

    Creso affords Pharma Dynamics sole distribution rights of its organic, broad spectrum hemp oil nutraceutical, cannaQIX10, across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda

    Read More
  • Lupin’s arm recalling 39,216 bottles of Lisinopril & Hydrochlorothiazide tablets from US
    26th Aug 2019, 10:21 AM

    This tablets were manufactured at the company’s Pithampur facility

    Read More
  • Lupin launches Fluoxetine Tablets USP
    22nd Aug 2019, 15:10 PM

    It is indicated in the treatment of MDD, OCD, Bulimia Nervosa and Panic Disorder

    Read More
  • Lupin divests Kyowa Criticare to Neopharma group
    22nd Aug 2019, 11:09 AM

    Under the terms of the agreement, the company has agreed to sell all the issued and outstanding share capital in Kyowa Criticare to neo ALA

    Read More
  • Lupin receives USFDA's approval for Hydrocortisone Valerate Cream
    16th Aug 2019, 15:29 PM

    It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients

    Read More
  • USFDA completes inspection of Lupin’s Nagpur facility
    8th Aug 2019, 14:55 PM

    The inspection for the oral solid facility at Nagpur closed without any 483 observations

    Read More
  • Lupin reports 49% rise in Q1 consolidated net profit
    8th Aug 2019, 09:36 AM

    Total consolidated income of the company increased by 11.15% at Rs 4,490.59 crore for Q1FY20

    Read More
  • Lupin - Quarterly Results
    7th Aug 2019, 13:49 PM

    Read More
  • ANSM completes inspection at Lupin’s Mandideep facility
    6th Aug 2019, 11:20 AM

    The inspection was conducted between April 8, 2019 and April 12, 2019

    Read More
  • Lupin receives EIR from USFDA for Aurangabad facility
    5th Aug 2019, 09:45 AM

    The facility was inspected by the USFDA between May 6, 2019 and May 15, 2019

    Read More
  • Lupin’s Nagpur facility wins ENR Global Best Project Award
    22nd Jul 2019, 10:07 AM

    Lupin's OSD and Injectable facility at Nagpur is Lupin's latest and most advanced manufacturing unit commissioned in 2018

    Read More
  • Lupin aims to launch new products across globe in current fiscal
    15th Jul 2019, 10:34 AM

    The new launches across the globe would help it achieve sustainable growth

    Read More
  • Lupin launches Imatinib Mesylate Tablets
    9th Jul 2019, 14:12 PM

    Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base), had annual sales of approximately $548 million in the US (IQVIA MAT May 2019)

    Read More
  • Lupin gets USFDA’s approval for Cinacalcet Tablets
    4th Jul 2019, 09:50 AM

    Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg, had annual sales of approximately $1,527 million in the US

    Read More
  • Lupin receives USFDA’s approval for Phenylephrine, Ketorolac Intraocular Solution
    3rd Jul 2019, 15:07 PM

    Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, had annual sales of approximately $42.8 million in the US

    Read More
  • Lupin gets tentative USFDA approval for Mirabegron Extended Release Tablets
    28th Jun 2019, 09:14 AM

    It is indicated for the treatment of Overactive Bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

    Read More
  • Lupin’s arm recalls over 18,000 bottles of Cefdinir in US market
    17th Jun 2019, 10:09 AM

    The recalling is due to metal piece identified in the product bottle prior to the reconstitution

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.